
Sonoma Pharmaceuticals SNOA
$ 2.85
1.42%
Quarterly report 2025-Q4
added 02-10-2026
Country |
|
IPO year |
- |
Industry |
Drug manufacturers |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
1.24 M |
Market Cap[1] |
$ 3.54 M |
EBITDA (LTM) |
$ -5.22 M |
P/E (LTM) |
-1.34 |
P/S (LTM) |
0.21 |
EPS (LTM) |
-2.19 |
Other stocks of industry "Drug manufacturers"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.69 | 0.25 % | $ 2.06 B | Nasdaq Global Select Market | ||
|
Canopy Growth Corporation
CGC
|
$ 1.07 | -2.29 % | $ 115 M | Nasdaq Global Select Market | ||
|
Cronos Group
CRON
|
$ 2.61 | -1.88 % | $ 1.35 B | Nasdaq Global Market | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 3.82 | -1.04 % | $ 53.7 M | Nasdaq Global Select Market | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Emergent BioSolutions
EBS
|
$ 10.89 | -1.4 % | $ 558 M | NYSE,SPB | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
Evolus
EOLS
|
$ 4.22 | -5.28 % | $ 262 M | Nasdaq Global Market | ||
|
China Pharma Holdings
CPHI
|
$ 0.64 | -4.45 % | $ 11.2 M | NYSE American | ||
|
Harrow Health
HROW
|
$ 47.94 | 0.48 % | $ 1.56 B | Nasdaq Global Market | ||
|
Pacira BioSciences
PCRX
|
$ 21.88 | 3.01 % | $ 1.01 B | Nasdaq Global Select Market,SPB | ||
|
OrganiGram Holdings
OGI
|
$ 1.3 | -6.47 % | $ 402 M | Nasdaq Global Select Market | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
Perrigo Company plc
PRGO
|
$ 14.59 | 1.28 % | $ 2 B | NYSE | ||
|
Bausch Health Companies
BHC
|
$ 6.07 | -1.3 % | $ 2.21 B | NYSE | ||
|
Sundial Growers
SNDL
|
$ 1.48 | -0.67 % | $ 3.37 M | Nasdaq Global Select Market | ||
|
Tilray
TLRY
|
$ 7.56 | -3.47 % | $ 4.67 B | Nasdaq Global Select Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
Organogenesis Holdings
ORGO
|
$ 3.72 | -3.12 % | $ 490 M | Nasdaq Capital Market | ||
|
cbdMD
YCBD
|
$ 0.83 | 2.45 % | $ 3.58 M | NYSE American | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
Aurora Cannabis
ACB
|
$ 3.45 | -3.1 % | $ 86.3 M | NYSE | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Rockwell Medical
RMTI
|
$ 1.07 | -1.83 % | $ 25 M | Nasdaq Global Market | ||
|
Relmada Therapeutics
RLMD
|
$ 3.97 | -1.24 % | $ 119 M | Nasdaq Global Select Market,SPB | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
Assertio Holdings
ASRT
|
$ 11.73 | 0.43 % | $ 833 M | Nasdaq Capital Market | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
Solid Biosciences
SLDB
|
$ 6.2 | -10.61 % | $ 253 M | Nasdaq Global Select Market,SPB | ||
|
SCYNEXIS
SCYX
|
$ 0.8 | -1.58 % | $ 38.3 M | Nasdaq Global Select Market | ||
|
Veru
VERU
|
$ 2.33 | 0.87 % | $ 314 M | Nasdaq Capital Market | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | ||
|
TherapeuticsMD
TXMD
|
$ 2.4 | 0.95 % | $ 25.1 M | Nasdaq Global Select Market | ||
|
Viatris
VTRS
|
$ 15.99 | 0.25 % | $ 19.4 B | Nasdaq Global Select Market,SPB | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.